NewAmsterdam Pharma (NAMS) Current Assets (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Current Assets data on file, last reported at $658.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 19.49% year-over-year to $658.0 million; the trailing twelve-month figure through Mar 2026 stood at $658.0 million (down 19.49% YoY), and the FY2025 full-year result was $675.7 million, down 21.74% from the prior year.
• Current Assets declined to $658.0 million in Q1 2026, from $675.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $863.4 million in Q4 2024 to a low of $346.8 million in Q4 2023.
• A 5-year average of $593.0 million and a median of $572.9 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 578.85% in 2022 and slipped 24.15% in 2023, its largest moves.
• Tracing NAMS's Current Assets over 5 years: stood at $457.2 million in 2022, then declined by 24.15% to $346.8 million in 2023, then jumped by 148.97% to $863.4 million in 2024, then fell by 21.74% to $675.7 million in 2025, then fell by 2.61% to $658.0 million in 2026.
• Business Quant data shows NAMS's Current Assets at $658.0 million in Q1 2026, $675.7 million in Q4 2025, and $732.3 million in Q3 2025.